Gene editing for heart disease
Verve Therapeutics is developing single-course gene editing treatments for cardiovascular disease. Their lead program uses base editing to permanently reduce LDL cholesterol by editing the PCSK9 gene in the liver.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| VERVE-101 | HeFH (high cholesterol) | Phase 1 | Base Editing |
| VERVE-102 | HeFH (next-gen) | Preclinical | Base Editing |
A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.
Eli Lilly acquired Verve Therapeutics for $1.3 billion in July 2025 — the biggest signal yet that big pharma believes in one-time genetic cures for chronic diseases.